Overview

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Status:
Active, not recruiting

Trial end date:
2022-02-25

Target enrollment:

Participant gender:

Summary

A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary peritoneal and / or fallopian tube cancer) or high grade endometrioid cancer with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) who have responded following platinum based chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborators:

European Network of Gynaecological Oncological Trial Groups (ENGOT)
European Network of Gynaecological Oncology Trial Groups (ENGOT)
Merck Sharp & Dohme Corp.
Myriad Genetic Laboratories, Inc.

Treatments:

Olaparib